Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement

Impact of Rapid Ventricular Pacing on Outcome After Transcatheter Aortic Valve Replacement

“…Alternative mechanism for AKI may be related to myocardial damage associated with myocardial ischemia during RVP. Elevations in myocardial biomarkers have been shown to be correlated with higher rates of AKI and poor long‐term outcome 10. Accordingly, the present study shows that RVP duration is associated with increased levels of myocardial biomarkers and higher rates of AKI.…”

Endovascular aneurysm repair (EVAR)– and transcatheter aortic valve replacement (TAVR)–associated acute kidney injury

“…and demonstrated a modest increase in GFR in the moderately impaired renal function group and a significant increase in GFR in those with severe CKD. There was no significant change in eGFR after TAVR in patients with normal renal function 98 . Patients who experienced an increase in GFR after TAVR by more than 22% had improved survival rate (p=0.0068), whereas a decrease in GFR by more than 15% was associated with decreased survival (p=0.0051).…”

“…100 Small observational studies, and a recent large cohort-study confirmed that TAVR via a transapical approach is associated with 4.7-9.3 times higher risk for AKI when compared to the transfemoral approach. 95,98,112 Patients who undergo a transapical approach usually have severe atherosclerotic disease that precludes them from transfemoral access. 113 This was elegantly shown by Thongprayoon et al; in patients undergoing the transapical approach for TAVR, PVD was more prevalent than those undergoing transfemoral approach (73% vs 44%; p<0.001).…”

Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation

“…In 60.8% (n ¼ 5,392) of patients, an Edwards SAPIEN or SAPIEN XT balloon-expandable valve (both Edwards Lifesciences, Irvine, California) was implanted, and in 21.4% (n ¼ 1,899) of patients, the self-expandable third-generation Medtronic CoreValve (Medtronic Inc., Minneapolis, Minnesota) prostheses were used, whereas 3 studies (comprising 15.8% of patients, n ¼ 1,583) did not specify the type of valve implanted. 20,22,23 Because of the infrequent reporting of conversion to surgery and intraprocedural death, no reliable incidence could be reported for these events. Table 2 summarizes procedural TAVI characteristics in the various studies.…”

“…4 3.1% and was above 20% in all studies, except for one (19 13%). 21 In those studies (n ¼ 5) in which reporting results was exclusively done using the Society of Thoracic Surgery score, 22,25,28,32,35 the mean risk of perioperative mortality was >5%. Diabetes mellitus was present in 24% (n ¼ 2,153) of patients, renal insufficiency in 48% (n ¼ 4,264), and a history of previous revascularization (either surgical or percutaneous) in 40% (n ¼ 3,541).…”